Alnylam pharmaceuticals, inc. ALNY.US Overview Analysis
ALNY AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
The stock, with its moderate value rating, suggests that existing positions can be retained. For initiating new positions, it's advisable to wait for a value score above 4 and a dividend score of 2 or higher.
ALNY Current Performance
-0.28%
Alnylam pharmaceuticals, inc.
2.24%
Avg of Sector
0.40%
S&P500
Top 10 High Relevance to ALNY
| Symbol | Company Name | Value | Trend | Swing Trading | Whale Interest | Dividend | Add to Watchlist |
|---|---|---|---|---|---|---|---|
IONS | Ionis pharmaceuticals inc | 2 | 1 | 4 | 3 | 1 | |
ADPT | Adaptive biotechnologies corp | 4 | 4 | 3 | 2 | 1 | |
KNSA | Kiniksa pharmaceuticals ltd | 4 | 5 | 2 | 1 | 1 | |
AGIO | Agios pharmaceuticals inc | 3 | 3 | 3 | 2 | 1 | |
XENE | Xenon pharmaceuticals inc | 2 | 3 | 4 | 3 | 1 |
- IONS Ionis pharmaceuticals incValue 2Trend 1Swing Trading 4Whale Interest 3Dividend 1See more
ALNY Profile
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. In addition, the Company develops Cemdisiran to treat complement-mediated diseases, Belcesiran for the treatment of alpha-1 liver disease, Elebsiran, Zilebesiran, ALN-APP, ALN-HSD, Fitusiran, and others.